Bibliographie

1. Hamm, C.W., *[Guidelines: Acute coronary syndrome (ACS). II: Acute coronary syndrome with ST-elevation].* Z Kardiol, 2004. **93**(4): p. 324-41.
2. De Luca, G., et al., *Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts.* Circulation, 2004. **109**(10): p. 1223-5.
3. Boersma, E., et al., *Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour.* Lancet, 1996. **348**(9030): p. 771-5.
4. Stenestrand, U. and L. Wallentin, *Early revascularisation and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study.* Lancet, 2002. **359**(9320): p. 1805-11.
5. de Vreede, J.J., et al., *Did prognosis after acute myocardial infarction change during the past 30 years? A meta-analysis.* J Am Coll Cardiol, 1991. **18**(3): p. 698-706.
6. Kannel, W.B. and D.L. McGee, *Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study.* Diabetes Care, 1979. **2**(2): p. 120-6.
7. Aronson, D., E.J. Rayfield, and J.H. Chesebro, *Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction.* Ann Intern Med, 1997. **126**(4): p. 296-306.
8. Mukamal, K.J., et al., *Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction.* Diabetes Care, 2001. **24**(8): p. 1422-7.
9. Grundy, S.M., et al., *Prevention Conference VI: Diabetes and Cardiovascular Disease: executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association.* Circulation, 2002. **105**(18): p. 2231-9.
10. Haffner, S.M., et al., *Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.* N Engl J Med, 1998. **339**(4): p. 229-34.
11. Mak, K.H., et al., *Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.* J Am Coll Cardiol, 1997. **30**(1): p. 171-9.
12. Elezi, S., et al., *Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement.* J Am Coll Cardiol, 1998. **32**(7): p. 1866-73.
13. Kip, K.E., et al., *Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry.* Circulation, 1996. **94**(8): p. 1818-25.
14. Mak, K.H. and E.J. Topol, *Emerging concepts in the management of acute myocardial infarction in patients with diabetes mellitus.* J Am Coll Cardiol, 2000. **35**(3): p. 563-8.
15. Gitt, A.K., *Einfluß des Diabetes mellitus auf die hospitale und 1-Jahres-Mortalität des ST und Non-ST-Hebungs-Myokardinfarktes in klinischer Praxis in den Jahren 2000-2002, Ergebnisse des ACOS Registers.* Pressespiegel der 3. Jahrestagung "Der herzkranke Diabetiker", 2003.
16. Pfeffer, M.A., et al., *Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators.* Jama, 1991. **266**(4): p. 528-32.
17. Keeley, E.C., J.A. Boura, and C.L. Grines, *Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.* Lancet, 2003. **361**(9351): p. 13-20.
18. Bruckenberger, E., *17. Herzbericht 2004 mit Transplantationschirurgie.* ISBN 3-00-017046-4, 2004.
19. Bonnefoy, E., et al., *Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study.* Lancet, 2002. **360**(9336): p. 825-9.
20. Widimsky, P., et al., *Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial--PRAGUE-2.* Eur Heart J, 2003. **24**(1): p. 94-104.
21. Bonnefoy, E., et al., *Is primary angioplasty more effective than prehospital fibrinolysis in diabetics with acute myocardial infarction? Data from the CAPTIM randomized clinical trial.* Eur Heart J, 2005.
22. Steg, P.G., et al., *Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial.* Circulation, 2003. **108**(23): p. 2851-6.

23. Silber, S., et al., *Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.* Eur Heart J, 2005. **26**(8): p. 804-47.

24. Ohman, E.M., et al., *Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators.* Circulation, 1997. **95**(4): p. 846-54.

25. Gurm, H.S., et al., *Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.* J Am Coll Cardiol, 2004. **43**(4): p. 542-8.

26. *Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.* Lancet, 2001. **358**(9282): p. 605-13.

27. Herrmann, H.C., et al., *Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial.* J Am Coll Cardiol, 2000. **36**(5): p. 1489-96.

28. Topol, E.J., et al., *Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.* Lancet, 1999. **354**(9195): p. 2019-24.

29. Brener, S.J., et al., *Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.* Circulation, 1998. **98**(8): p. 734-41.

30. *Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.* Lancet, 2000. **356**(9247): p. 2037-44.

31. Chan, A.W. and D.J. Moliterno, *Defining the role of abciximab for acute coronary syndromes: lessons from CADILLAC, ADMIRAL, GUSTO IV, GUSTO V, and TARGET.* Curr Opin Cardiol, 2001. **16**(6): p. 375-83.

32. Roffi, M., et al., *Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.* Circulation, 2001. **104**(23): p. 2767-71.

33. Blankenship, J.C., et al., *Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial.* J Am Coll Cardiol, 2001. **38**(3): p. 653-8.

34. Topol, E.J., *Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.* Lancet, 2001. **357**(9272): p. 1905-14.

35. Antman, E.M., et al., *Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators.* Circulation, 1999. **99**(21): p. 2720-32.

36. Baim, D.S., Grossmann, W., *Cardiac catheterization, angiography and intervention.* . 1996, Baltimore: Williams&Wikins. 199-201.

37. Kaltenbach, M., Kutschera, J., Sparn, F.,, *Documentation of findings of coronary heart disease.* Coronary heart disease. 1973, Stuttgart: Thieme. 112-115.

38. Ravkilde, J., et al., *Risk stratification in suspected acute myocardial infarction based on a sensitive immunoassay for serum creatine kinase isoenzyme MB. A 2.5-year follow-up study in 156 consecutive patients.* Cardiology, 1992. **80**(2): p. 143-51.

39. Pettersson, T., O. Ohlsson, and N. Tryding, *Increased CKMB (mass concentration) in patients without traditional evidence of acute myocardial infarction. A risk indicator of coronary death.* Eur Heart J, 1992. **13**(10): p. 1387-92.

40. *Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group.* Lancet, 1988. **2**(8607): p. 349-60.

41. *Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.* Bmj, 2002. **324**(7329): p. 71-86.

42. de Bono, D.P., et al., *Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial.* Br Heart J, 1992. **67**(2): p. 122-8.

43. Hsia, J., et al., *A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.* N Engl J Med, 1990. **323**(21): p. 1433-7.

44.   Bertrand, M.E., et al., *Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS).* Circulation, 2000. **102**(6): p. 624-9.

45.   Lefkovits, J., et al., *Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators.* Am J Cardiol, 1996. **77**(12): p. 1045-51.

46.   Montalescot, G., et al., *Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.* Jama, 2004. **292**(3): p. 362-6.

47.   Topol, E.J., et al., *Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.* N Engl J Med, 2001. **344**(25): p. 1888-94.

48.   *Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.* Circulation, 1997. **96**(5): p. 1445-53.

49.   *Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.* N Engl J Med, 1998. **339**(7): p. 436-43.

50.   *The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators.* N Engl J Med, 1993. **329**(22): p. 1615-22.

51.   Califf, R.M., et al., *One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators.* Circulation, 1996. **94**(6): p. 1233-8.

52.   Bode, C., et al., *Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.* Circulation, 1996. **94**(5): p. 891-8.

53.   Topol, E.J., et al., *Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial.* Circulation, 2000. **102**(15): p. 1761-5.

54.   Sinnaeve, P., et al., *One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction.* Am Heart J, 2003. **146**(1): p. 27-32.

55.   Braunwald, E., *in Harrison´s Principles of Internal Medicine.* 1998. **14th Edition**: p. 128.

56.   Gibson, C.M., et al., *TIMI frame count: a quantitative method of assessing coronary artery flow.* Circulation, 1996. **93**(5): p. 879-88.

57.   Reimer, K.A., et al., *The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs.* Circulation, 1977. **56**(5): p. 786-94.

58.   Boersma, E., et al., *Acute myocardial infarction.* Lancet, 2003. **361**(9360): p. 847-58.

59.   Reimer, K.A. and R.B. Jennings, *The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow.* Lab Invest, 1979. **40**(6): p. 633-44.

60.   Simes, R.J., et al., *Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators.* Circulation, 1995. **91**(7): p. 1923-8.

61.   Davies, M.J., *The pathophysiology of acute coronary syndromes.* Heart, 2000. **83**(3): p. 361-6.

62.   Gronholdt, M.L., S. Dalager-Pedersen, and E. Falk, *Coronary atherosclerosis: determinants of plaque rupture.* Eur Heart J, 1998. **19 Suppl C**: p. C24-9.

63.   Falk, E., P.K. Shah, and V. Fuster, *Coronary plaque disruption.* Circulation, 1995. **92**(3): p. 657-71.

64.   Giroud, D., et al., *Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography.* Am J Cardiol, 1992. **69**(8): p. 729-32.

65.   Fox, K.A., et al., *Management of acute coronary syndromes. Variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE).* Eur Heart J, 2002. **23**(15): p. 1177-89.

66.   Fox, K.A., et al., *The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment.* Eur Heart J, 2000. **21**(17): p. 1440-9.

67.   Gottwik, M., et al., *Differences in treatment and outcome of patients with acute myocardial infarction admitted to hospitals with compared to without departments of cardiology; results from the pooled data of the Maximal Individual Therapy in Acute Myocardial Infarction (MITRA 1+2) Registries and the Myocardial Infarction Registry (MIR).* Eur Heart J, 2001. **22**(19): p. 1794-801.

68.   Ross, A.M., et al., *Extended mortality benefit of early postinfarction reperfusion. GUSTO-I Angiographic Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Trial.* Circulation, 1998. **97**(16): p. 1549-56.

69.   Grines, C., et al., *Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials.* Am Heart J, 2003. **145**(1): p. 47-57.

70.   Grines, C.L., et al., *Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group.* N Engl J Med, 1999. **341**(26): p. 1949-56.

71.   Stone, G.W., et al., *Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.* N Engl J Med, 2002. **346**(13): p. 957-66.

72.   Kastrati, A., et al., *Primary intracoronary stenting in acute myocardial infarction: long-term clinical and angiographic follow-up and risk factor analysis.* Am Heart J, 2000. **139**(2 Pt 1): p. 208-16.

73.   Schomig, A., et al., *Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators.* N Engl J Med, 2000. **343**(6): p. 385-91.

74.   Kandzari, D.E., et al., *Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials.* Am Heart J, 2004. **147**(3): p. 457-62.

75.   Godicke, J., et al., *Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies.* Am Heart J, 2005. **150**(5): p. 1015.

76.   Morrow, D.A., et al., *Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early Retavase-Thrombolysis in Myocardial Infarction (ER-TIMI) 19 trial.* J Am Coll Cardiol, 2002. **40**(1): p. 71-7.

77.   Arntz, H.R., U. Zeymer, and P. Schwimmbeck, *[Thrombolysis in ST-elevation myocardial infarction. Current role in the light of recent studies].* Anaesthesist, 2004. **53**(5): p. 445-54.

78.   *Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. The European Myocardial Infarction Project Group.* N Engl J Med, 1993. **329**(6): p. 383-9.

79.   Zijlstra, F., et al., *Clinical characteristics and outcome of patients with early (<2 h), intermediate (2-4 h) and late (>4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction.* Eur Heart J, 2002. **23**(7): p. 550-7.

80.   Andersen, H.R., et al., *A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction.* N Engl J Med, 2003. **349**(8): p. 733-42.

81.   Moon, J.C., P.R. Kalra, and A.J. Coats, *DANAMI-2: is primary angioplasty superior to thrombolysis in acute MI when the patient has to be transferred to an invasive centre?* Int J Cardiol, 2002. **85**(2-3): p. 199-201.

82.   Ellis, S.G., et al., *Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: insights from the RESCUE I, RESCUE II, and other contemporary clinical experiences.* Am Heart J, 2000. **139**(6): p. 1046-53.

83.   *Berliner Herzinfarktregister.* http://www.herzinfarktregister.de.

84.   Kastrati, A., et al., *Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial.* Lancet, 2002. **359**(9310): p. 920-5.

85.   Popitean, L., et al., *Factors affecting the management of outcome in elderly patients with acute myocardial infarction Particularly with regard to reperfusion. Data from the French regional RICO survey.* Gerontology, 2005. **51**(6): p. 409-15.

86.   McClelland, A.J., et al., *Percutaneous coronary intervention and 1 year survival in patients treated with fibrinolytic therapy for acute ST-elevation myocardial infarction.* Eur Heart J, 2005. **26**(6): p. 544-8.

87.   De Luca, G., et al., *Preprocedural Thrombolysis in Myocardial Infarction (TIMI) flow significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute anterior myocardial infarction treated by primary angioplasty.* Am Heart J, 2005. **150**(4): p. 827-31.

88.   van 't Hof, A.W., et al., *Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group.* Circulation, 1998. **97**(23): p. 2302-6.

89. Taher, T., et al., *Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electro-cardiographic Substudy.* J Am Coll Cardiol, 2004. **44**(1): p. 38-43.

90. *Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial.* Lancet, 2006. **367**(9510): p. 569-78.

91. Van de Werf, F., *The Assessment of the safety and efficacy of a new treatment strategy for acute myocardial infarction - ASSENT-4 PCI.* 2005.

92. Antman, E.M., et al., *Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial.* Circulation, 2002. **105**(14): p. 1642-9.

93. Hanania, G., et al., *Management and in-hospital outcome of patients with acute myocardial infarction admitted to intensive care units at the turn of the century: results from the French nationwide USIC 2000 registry.* Heart, 2004. **90**(12): p. 1404-10.

94. Danchin, N., et al., *Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry.* Circulation, 2004. **110**(14): p. 1909-15.

95. Goldberg, R.J., et al., *Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (the Global Registry of Acute Coronary Events [GRACE]).* Am J Cardiol, 2004. **93**(3): p. 288-93.

96. Keeley, E.C., J.A. Boura, and C.L. Grines, *Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials.* Lancet, 2006. **367**(9510): p. 579-88.

97. *Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated ADdressing the Value of facilitated ANgioplasty after Combination therapy or Eptifibatide monotherapy in acute Myocardial Infarction (ADVANCE MI) trial.* Am Heart J, 2005. **150**(1): p. 116-22.

98. Thiele, H., et al., *Comparison of pre-hospital combination-fibrinolysis plus conventional care with pre-hospital combination-fibrinolysis plus facilitated percutaneous coronary intervention in acute myocardial infarction.* Eur Heart J, 2005. **26**(19): p. 1956-63.

99. King, H., R.E. Aubert, and W.H. Herman, *Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections.* Diabetes Care, 1998. **21**(9): p. 1414-31.

100. Rathmann, W., et al., *High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000.* Diabetologia, 2003. **46**(2): p. 182-9.

101. Selvin, E., et al., *Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus.* Ann Intern Med, 2004. **141**(6): p. 421-31.

102. Sattar, N., et al., *Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study.* Circulation, 2003. **108**(4): p. 414-9.

103. Ford, E.S., W.H. Giles, and A.H. Mokdad, *Increasing prevalence of the metabolic syndrome among u.s. Adults.* Diabetes Care, 2004. **27**(10): p. 2444-9.

104. Fox, C.S., et al., *The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study.* Diabetes Care, 2004. **27**(3): p. 704-8.

105. John, J.M. and D.L. Bhatt, *Management of acute coronary syndrome in diabetes mellitus.* Herz, 2004. **29**(5): p. 532-41.

106. Moss, S.E., R. Klein, and B.E. Klein, *Cause-specific mortality in a population-based study of diabetes.* Am J Public Health, 1991. **81**(9): p. 1158-62.

107. Stuckey, T.D., et al., *Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial).* Am J Cardiol, 2005. **95**(1): p. 1-7.

108. Marso, S.P., et al., *Diabetes mellitus is associated with a shift in the temporal risk profile of in-hospital death after percutaneous coronary intervention: an analysis of 25,223 patients over 20 years.* Am Heart J, 2003. **145**(2): p. 270-7.

109. Roehnisch, J.-U., et al., *Diabetes mellitus und Herzinfarkt - Daten zur Behandlung und Krankenhausmortalität aus dem Berliner Herzinfarktregister.* www.herzinfarktregister.de, 2004.

110. Marchant, B., et al., *Silent myocardial ischemia: role of subclinical neuropathy in patients with and without diabetes.* J Am Coll Cardiol, 1993. **22**(5): p. 1433-7.

111. *Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 pa-*

tients. *Fibrinolytic Therapy Trialists' (FTT) Collaborative Group.* Lancet, 1994. **343**(8893): p. 311-22.

112. Goraya, T.Y., et al., *Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study.* J Am Coll Cardiol, 2002. **40**(5): p. 946-53.

113. Brownlee, M., A. Cerami, and H. Vlassara, *Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.* N Engl J Med, 1988. **318**(20): p. 1315-21.

114. Schmidt, A.M., et al., *Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes.* J Clin Invest, 1995. **96**(3): p. 1395-403.

115. Bierhaus, A., et al., *AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept.* Cardiovasc Res, 1998. **37**(3): p. 586-600.

116. Kornowski, R., et al., *Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study.* Circulation, 1997. **95**(6): p. 1366-9.

117. Tschoepe, D., et al., *Evidence for abnormal platelet glycoprotein expression in diabetes mellitus.* Eur J Clin Invest, 1990. **20**(2): p. 166-70.

118. Knobler, H., et al., *Shear-induced platelet adhesion and aggregation on subendothelium are increased in diabetic patients.* Thromb Res, 1998. **90**(4): p. 181-90.

119. Ostermann, H. and J. van de Loo, *Factors of the hemostatic system in diabetic patients. A survey of controlled studies.* Haemostasis, 1986. **16**(6): p. 386-416.

120. Carr, M.E., *Diabetes mellitus: a hypercoagulable state.* J Diabetes Complications, 2001. **15**(1): p. 44-54.

121. Libby, P. and D.I. Simon, *Inflammation and thrombosis: the clot thickens.* Circulation, 2001. **103**(13): p. 1718-20.

122. Henn, V., et al., *CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells.* Nature, 1998. **391**(6667): p. 591-4.

123. Moreno, P.R., et al., *Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture.* Circulation, 1994. **90**(2): p. 775-8.

124. Buja, L.M. and J.T. Willerson, *Role of inflammation in coronary plaque disruption.* Circulation, 1994. **89**(1): p. 503-5.

125. Woodfield, S.L., et al., *Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience.* J Am Coll Cardiol, 1996. **28**(7): p. 1661-9.

126. Zuanetti, G., et al., *Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study.* J Am Coll Cardiol, 1993. **22**(7): p. 1788-94.

127. Granger, C.B., et al., *Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group.* J Am Coll Cardiol, 1993. **21**(4): p. 920-5.

128. Zairis, M.N., et al., *Type 2 diabetes and intravenous thrombolysis outcome in the setting of ST elevation myocardial infarction.* Diabetes Care, 2004. **27**(4): p. 967-71.

129. Hasdai, D., et al., *Diabetes mellitus and outcome after primary coronary angioplasty for acute myocardial infarction: lessons from the GUSTO-IIb Angioplasty Substudy. Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes.* J Am Coll Cardiol, 2000. **35**(6): p. 1502-12.

130. van der Schaaf, R.J., et al., *Primary PCI for acute STEMI patients with and without diabetes mellitus.* Heart, 2005.

131. Prasad, A., et al., *Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction.* J Am Coll Cardiol, 2005. **45**(4): p. 508-14.

132. Van Belle, E., et al., *Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary vessels.* Circulation, 1997. **96**(5): p. 1454-60.

133. Van Belle, E., et al., *Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients.* J Am Coll Cardiol, 2002. **40**(3): p. 410-7.

134. Gilbert, J., J. Raboud, and B. Zinman, *Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting.* Diabetes Care, 2004. **27**(4): p. 990-4.

135. Silva, J.A., et al., *Primary stenting in acute myocardial infarction: influence of diabetes mellitus in angiographic results and clinical outcome.* Am Heart J, 1999. **138**(3 Pt 1): p. 446-55.

136. Kastrati, A., et al., *Predictive factors of restenosis after coronary stent placement.* J Am Coll Cardiol, 1997. **30**(6): p. 1428-36.

108

137. Bhatt, D.L., et al., *Abciximab reduces mortality in diabetics following percutaneous coronary intervention.* J Am Coll Cardiol, 2000. **35**(4): p. 922-8.

138. Marso, S.P., et al., *Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.* Circulation, 1999. **100**(25): p. 2477-84.

139. Moses, J.W., et al., *Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.* N Engl J Med, 2003. **349**(14): p. 1315-23.

140. Stone, G.W., et al., *One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.* Circulation, 2004. **109**(16): p. 1942-7.

141. Gitt, A.K., et al., *Intensive treatment of coronary artery disease in diabetic patients in clinical practice: results of the MITRA study.* Acta Diabetol, 2003. **40 Suppl 2**: p. S343-7.

142. Lindholm, M.G., et al., *Diabetes mellitus and cardiogenic shock in acute myocardial infarction.* Eur J Heart Fail, 2005. **7**(5): p. 834-9.

143. Hermiller, J.B., et al., *Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial.* J Am Coll Cardiol, 2005. **45**(8): p. 1172-9.

144. Abizaid, A., et al., *Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial.* Eur Heart J, 2004. **25**(2): p. 107-12.

145. Schroder, R., et al., *Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial.* J Am Coll Cardiol, 1995. **26**(7): p. 1657-64.

146. Dong, J., et al., *Early resolution of ST-segment elevation correlates with myocardial salvage assessed by Tc-99m sestamibi scintigraphy in patients with acute myocardial infarction after mechanical or thrombolytic reperfusion therapy.* Circulation, 2002. **105**(25): p. 2946-9.

147. Angeja, B.G., et al., *Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy.* Am Heart J, 2002. **144**(4): p. 649-56.

148. *Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial.* Lancet, 2002. **360**(9338): p. 965-70.

149. Rodriguez, A., et al., *Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators.* J Am Coll Cardiol, 2001. **37**(1): p. 51-8.

150. Abizaid, A., et al., *Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial.* Circulation, 2001. **104**(5): p. 533-8.

151. Bakhai, A., et al., *Diabetic patients with acute coronary syndromes in the UK: high risk and under treated. Results from the prospective registry of acute ischaemic syndromes in the UK (PRAIS-UK).* Int J Cardiol, 2005. **100**(1): p. 79-84.

152. Taubert, G., et al., *Prevalence, predictors, and consequences of unrecognized diabetes mellitus in 3266 patients scheduled for coronary angiography.* Am Heart J, 2003. **145**(2): p. 285-91.

153. Bartnik, M., et al., *Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction.* Eur Heart J, 2004. **25**(22): p. 1990-7.

154. Kereiakes, D.J. and J.J. Young, *Percutaneous coronary revascularization of diabetic patients in the era of drug-eluting stents.* Rev Cardiovasc Med, 2005. **6 Suppl 1**: p. S48-58.